Unknown

Dataset Information

0

Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma.

ABSTRACT:

SUBMITTER: Hood K 

PROVIDER: S-EPMC5226312 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma.

Hood Katelyn K   Shah Arpita A  

Journal of the advanced practitioner in oncology 20160301 2

Similar Datasets

Unknown Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
| S-EPMC4216035 | biostudies-literature
Unknown Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma.
| S-EPMC9913081 | biostudies-literature
Unknown Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma.
| S-EPMC11401221 | biostudies-literature
Unknown The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
| S-EPMC5836501 | biostudies-literature
Unknown Therapeutic options for relapsed/refractory mantle cell lymphoma.
| S-EPMC9710495 | biostudies-literature
Unknown Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
| S-EPMC8954159 | biostudies-literature
Unknown New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.
| S-EPMC4461120 | biostudies-literature
Unknown Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients.
| S-EPMC10786139 | biostudies-literature
Unknown Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma.
| S-EPMC7738829 | biostudies-literature
Unknown Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.
| S-EPMC9234908 | biostudies-literature